New peptide receptor radionuclide therapy of invasive cancer cells: In vivo studies using 177Lu-DOTA-AE105 targeting uPAR in human colorectal cancer xenografts

Nuclear Medicine and Biology

Volumn 39, Issue 7, 2012, Pages 962-969

  Persson, Morten ^a,b,c,d   Rasmussen, Palle ^e   Madsen, Jacob ^b   Ploug, Michael ^a,d   Kjaer, Andreas ^a,b,c  

^a The Danish Chinese Center for Proteases and Cancer   (Denmark)

^b Rigshospitalet   (Denmark)

^c UNIVERSITY OF COPENHAGEN   (Denmark)

^d FINSEN LABORATORY   (Denmark)

^e TECHNICAL UNIVERSITY OF DENMARK   (Denmark)

Author keywords

177Lu; Imaging; In vivo; PRRT; UPAR

Indexed keywords

3' FLUOROTHYMIDINE F 18; COPPER 64; EOSIN; HEMATOXYLIN; LUTETIUM 177; PLASMINOGEN ACTIVATOR INHIBITOR TETRAXETAN LUTETIUM LU 177; RADIOPHARMACEUTICAL AGENT; UNCLASSIFIED DRUG; UROKINASE RECEPTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BODY WEIGHT; CANCER CELL CULTURE; CANCER INVASION; COLORECTAL CANCER; COMPUTER ASSISTED EMISSION TOMOGRAPHY; CONTROLLED STUDY; CORRELATION ANALYSIS; DOSIMETRY; DRUG ACCUMULATION; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG STRUCTURE; DRUG TARGETING; HISTOPATHOLOGY; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; IN VIVO STUDY; ISOTOPE LABELING; KIDNEY PARENCHYMA; MOUSE; NEPHROTOXICITY; NONHUMAN; PROTEIN EXPRESSION; RADIOACTIVITY; RADIOISOTOPE THERAPY; TUMOR VOLUME; TUMOR XENOGRAFT;

ANIMALS; BETA PARTICLES; CELL TRANSFORMATION, NEOPLASTIC; COLORECTAL NEOPLASMS; DIDEOXYNUCLEOSIDES; FEMALE; HETEROCYCLIC COMPOUNDS, 1-RING; HT29 CELLS; HUMANS; LUTETIUM; MICE; MOLECULAR TARGETED THERAPY; NEOPLASM INVASIVENESS; OLIGOPEPTIDES; POSITRON-EMISSION TOMOGRAPHY; RADIOISOTOPES; RECEPTORS, UROKINASE PLASMINOGEN ACTIVATOR; SUBSTRATE SPECIFICITY;

EID: 84866041733     PISSN: 09698051     EISSN: 18729614     Source Type: Journal    
DOI: 10.1016/j.nucmedbio.2012.05.007     Document Type: Article

References (37)

1. Jemal A., Siegel R., Xu J., Ward E. Cancer statistics, 2010. CA Cancer J Clin 2010, 60:277-300.
2. Ferlay J., Shin H.R., Bray F., Forman D., Mathers C., Parkin D.M. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 2010, 127:2893-2917.
3. Glazer E.S., Beaty K., Abdalla E.K., Vauthey J.N., Curley S.A. Effectiveness of positron emission tomography for predicting chemotherapy response in colorectal cancer liver metastases. Arch Surg 2010, 145:340-345. [discussion 5].
4. Kriegbaum M.C., Persson M., Haldager L., Alpizar-Alpizar W., Jacobsen B., Gårdsvoll H., et al. Rational targeting of the urokinase receptor (uPAR): development of inhibitors and non-invasive imaging probes. Curr Drug Targets 2010, 12:12.
5. Mazar A.P. The urokinase plasminogen activator receptor (uPAR) as a target for the diagnosis and therapy of cancer. Anticancer Drugs 2001, 12:387-400.
6. Jacobsen B., Ploug M. The urokinase receptor and its structural homologue C4.4A in human cancer: expression, prognosis and pharmacological inhibition. Curr Med Chem 2008, 15:2559-2573.
7. Rasch M.G., Lund I.K., Almasi C.E., Hoyer-Hansen G. Intact and cleaved uPAR forms: diagnostic and prognostic value in cancer. Front Biosci 2008, 13:6752-6762.
8. Ganesh S., Sier C.F., Griffioen G., Vloedgraven H.J., de Boer A., Welvaart K., et al. Prognostic relevance of plasminogen activators and their inhibitors in colorectal cancer. Cancer Res 1994, 54:4065-4071.
9. Ganesh S., Sier C.F., Heerding M.M., Griffioen G., Lamers C.B., Verspaget H.W. Urokinase receptor and colorectal cancer survival. Lancet 1994, 344:401-402.
10. Ganesh S., Sier C.F., Heerding M.M., van Krieken J.H., Griffioen G., Welvaart K., et al. Contribution of plasminogen activators and their inhibitors to the survival prognosis of patients with Dukes' stage B and C colorectal cancer. Br J Cancer 1997, 75:1793-1801.
11. Stephens R.W., Nielsen H.J., Christensen I.J., Thorlacius-Ussing O., Sorensen S., Dano K., et al. Plasma urokinase receptor levels in patients with colorectal cancer: relationship to prognosis. J Natl Cancer Inst 1999, 91:869-874.
12. Lomholt A.F., Christensen I.J., Hoyer-Hansen G., Nielsen H.J. Prognostic value of intact and cleaved forms of the urokinase plasminogen activator receptor in a retrospective study of 518 colorectal cancer patients. Acta Oncol 2010, 49:805-811.
13. Illemann M., Bird N., Majeed A., Laerum O.D., Lund L.R., Dano K., et al. Two distinct expression patterns of urokinase, urokinase receptor and plasminogen activator inhibitor-1 in colon cancer liver metastases. Int J Cancer 2009, 124:1860-1870.
14. Wang Y., Liang X., Wu S., Murrell G.A., Doe W.F. Inhibition of colon cancer metastasis by a 3'- end antisense urokinase receptor mRNA in a nude mouse model. Int J Cancer 2001, 92:257-262.
15. Ahmed N., Oliva K., Wang Y., Quinn M., Rice G. Downregulation of urokinase plasminogen activator receptor expression inhibits Erk signalling with concomitant suppression of invasiveness due to loss of uPAR-beta1 integrin complex in colon cancer cells. Br J Cancer 2003, 89:374-384.
16. Van Buren G., Gray M.J., Dallas N.A., Xia L., Lim S.J., Fan F., et al. Targeting the urokinase plasminogen activator receptor with a monoclonal antibody impairs the growth of human colorectal cancer in the liver. Cancer 2009, 115:3360-3368.
17. Lee D.Y., Li K.C. Molecular theranostics: a primer for the imaging professional. AJR Am J Roentgenol 2011, 197:318-324.
18. Kwekkeboom D.J., de Herder W.W., Kam B.L., van Eijck C.H., van Essen M., Kooij P.P., et al. Treatment with the radiolabeled somatostatin analog [177 Lu-DOTA 0, Tyr3]octreotate: toxicity, efficacy, and survival. J Clin Oncol 2008, 26:2124-2130.
19. Jiang L., Miao Z., Kimura R.H., Liu H., Cochran J.R., Culter C.S., et al. Preliminary evaluation of (177)Lu-labeled knottin peptides for integrin receptor-targeted radionuclide therapy. Eur J Nucl Med Mol Imaging 2011, 38:613-622.
20. Persson M., Gedda L., Lundqvist H., Tolmachev V., Nordgren H., Malmstrom P.U., et al. [177Lu]pertuzumab: experimental therapy of HER-2-expressing xenografts. Cancer Res 2007, 67:326-331.
21. Tolmachev V., Orlova A., Pehrson R., Galli J., Baastrup B., Andersson K., et al. Radionuclide therapy of HER2-positive microxenografts using a 177Lu-labeled HER2-specific Affibody molecule. Cancer Res 2007, 67:2773-2782.
22. Wild D., Frischknecht M., Zhang H., Morgenstern A., Bruchertseifer F., Boisclair J., et al. Alpha- versus beta-particle radiopeptide therapy in a human prostate cancer model (213Bi-DOTA-PESIN and 213Bi-AMBA versus 177Lu-DOTA-PESIN). Cancer Res 2011, 71:1009-1018.
23. Blankenberg F.G., Levashova Z., Goris M.G., Hamby C.V., Backer M.V., Backer J.M. Targeted systemic radiotherapy with scVEGF/177Lu leads to sustained disruption of the tumor vasculature and intratumoral apoptosis. J Nucl Med 2011, 52:1630-1637.
24. Akinlolu O., Ottolino-Perry K., McCart J.A., Reilly R.M. Antiproliferative effects of 111In- or 177Lu-DOTATOC on cells exposed to low multiplicity-of-infection double-deleted vaccinia virus encoding somatostatin subtype-2 receptor. Cancer Biother Radiopharm 2010, 25:325-333.
25. Persson M., Madsen J., Ostergaard S., Jensen M.M., Jorgensen J.T., Juhl K., et al. Quantitative PET of human urokinase-type plasminogen activator receptor with 64Cu-DOTA-AE105: implications for visualizing cancer invasion. J Nucl Med 2012, 53:138-145.
26. Li Z.B., Niu G., Wang H., He L., Yang L., Ploug M., et al. Imaging of urokinase-type plasminogen activator receptor expression using a 64Cu-labeled linear peptide antagonist by microPET. Clin Cancer Res 2008, 14:4758-4766.
27. Ploug M., Ostergaard S., Gardsvoll H., Kovalski K., Holst-Hansen C., Holm A., et al. Peptide-derived antagonists of the urokinase receptor. affinity maturation by combinatorial chemistry, identification of functional epitopes, and inhibitory effect on cancer cell intravasation. Biochemistry 2001, 40:12157-12168.
28. Persson M., Madsen J., Ostergaard S., Ploug M., Kjaer A. (68)Ga-labeling and in vivo evaluation of a uPAR binding DOTA- and NODAGA-conjugated peptide for PET imaging of invasive cancers. Nucl Med Biol 2012.
29. Jacobsen B., Gardsvoll H., Juhl Funch G., Ostergaard S., Barkholt V., Ploug M. One-step affinity purification of recombinant urokinase-type plasminogen activator receptor using a synthetic peptide developed by combinatorial chemistry. Protein Expr Purif 2007, 52:286-296.
30. Lin L., Gardsvoll H., Huai Q., Huang M., Ploug M. Structure-based engineering of species selectivity in the interaction between urokinase and its receptor: implication for preclinical cancer therapy. J Biol Chem 2010, 285:10982-10992.
31. Ronne E., Hoyer-Hansen G., Brunner N., Pedersen H., Rank F., Osborne C.K., et al. Urokinase receptor in breast cancer tissue extracts. Enzyme-linked immunosorbent assay with a combination of mono- and polyclonal antibodies. Breast Cancer Res Treat 1995, 33:199-207.
32. Qu C.F., Song E.Y., Li Y., Rizvi S.M., Raja C., Smith R., et al. Pre-clinical study of 213Bi labeled PAI2 for the control of micrometastatic pancreatic cancer. Clin Exp Metastasis 2005, 22:575-586.
33. Gotthardt M., van Eerd-Vismale J., Oyen W.J., de Jong M., Zhang H., Rolleman E., et al. Indication for different mechanisms of kidney uptake of radiolabeled peptides. J Nucl Med 2007, 48:596-601.
34. Rolleman E.J., Melis M., Valkema R., Boerman O.C., Krenning E.P., de Jong M. Kidney protection during peptide receptor radionuclide therapy with somatostatin analogues. Eur J Nucl Med Mol Imaging 2010, 37:1018-1031.
35. Jensen M.M., Erichsen K.D., Bjorkling F., Madsen J., Jensen P.B., Hojgaard L., et al. Early detection of response to experimental chemotherapeutic Top216 with [18F]FLT and [18F]FDG PET in human ovary cancer xenografts in mice. PLoS One 2010, 5:e12965.
36. Herrmann K., Buck A.K., Schuster T., Junger A., Wieder H.A., Graf N., et al. Predictive value of initial 18F-FLT uptake in patients with aggressive non-Hodgkin lymphoma receiving R-CHOP treatment. J Nucl Med 2011, 52:690-696.
37. Zander T., Scheffler M., Nogova L., Kobe C., Engel-Riedel W., Hellmich M., et al. Early prediction of nonprogression in advanced non-small-cell lung cancer treated with erlotinib by using [(18)F]fluorodeoxyglucose and [(18)F]fluorothymidine positron emission tomography. J Clin Oncol 2011, 29:1701-1708.